Engineering CAR-T cell therapies for digestive tract cancer: advances, challenges, and strategies to overcome tumor heterogeneity and immunosuppressive barriers.
CAR-T therapy yields remarkable clinical efficacy against hematological malignancies, yet its translation to solid tumors, particularly gastrointestinal cancers, is impeded by multiple bottlenecks including antigen heterogeneity, immunosuppressive tumor microenvironments and metabolic inhibition. This review systematic...